var data={"title":"Quadrivalent meningococcal conjugate (D) vaccine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Quadrivalent meningococcal conjugate (D) vaccine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6526?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=quadrivalent-meningococcal-conjugate-d-vaccine-drug-information\" class=\"drug drug_general\">see &quot;Quadrivalent meningococcal conjugate (D) vaccine: Drug information&quot;</a> and <a href=\"topic.htm?path=quadrivalent-meningococcal-conjugate-d-vaccine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Quadrivalent meningococcal conjugate (D) vaccine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192572\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Menactra;</li>\n      <li>Menveo</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12592734\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Menactra;</li>\n      <li>Menveo</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060172\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Vaccine</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vaccine, Inactivated Bacteria</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060165\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=quadrivalent-meningococcal-conjugate-d-vaccine-drug-information\" class=\"drug drug_general\">see &quot;Quadrivalent meningococcal conjugate (D) vaccine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Use of the abbreviation, MenACWY, refers to either meningococcal quadrivalent conjugate vaccine. MenACWY-CRM refers specifically to Menveo; MenACWY-D refers specifically to Menactra. Consult CDC/ACIP annual immunization schedules for additional information including specific detailed recommendations for catch-up scenarios and/or care of patients with high-risk conditions. According to ACIP, doses administered &le;4 days before minimum interval or age are considered valid; however, local or state mandates may supersede this timeframe (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Primary immunization:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Manufacturer's labeling: General dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Menactra:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &ge;9 months and Children &lt;2 years: IM: 0.5 mL per dose for a total of 2 doses given 3 months apart</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;2 years and Adolescents: IM: 0.5 mL per dose as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Menveo: Age at initiation of vaccine series:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants 2 to &lt;7 months: IM: 0.5 mL per dose for a total of 4 doses administered as follows: 2, 4, 6, and 12 months of age</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children 7 to 23 months: IM: 0.5 mL per dose for a total of 2 doses. The second dose should be given during the second year of life and at least 3 months after the first dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to &lt;6 years: IM: 0.5 mL per dose as a single dose; for children at continued high risk of meningococcal disease, may consider an additional dose given 2 months after the first dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;6 years and Adolescents: IM: 0.5 mL per dose as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CDC (ACIP) recommendations (ACIP [Robinson 2017]; CDC/ACIP [Cohn 2013]; CDC/ACIP [MacNeil 2014]; CDC/ACIP [MacNeil 2016]):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Primary vaccination for patients <b>NOT</b> at increased risk for meningococcal disease: </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children &lt;11 years: Not routinely recommended; see dosing for persons at increased risk</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 11 to 12 years: IM: 0.5 mL per dose as a single dose. Children not at increased risk for meningococcal disease who may have been previously vaccinated with Hib-MenCY-TT (MenHibrix) or MenACWY (Menactra or Menveo) prior to their 10th birthday; should receive the routinely recommended dose of MenACWY at 11 to 12 years</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents: IM: 0.5 mL per dose as a single dose if not previously vaccinated</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Primary vaccination for patients at increased risk for meningococcal disease: </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &ge;2 months and Children &lt;2 years:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Anatomic or functional asplenia (including sickle cell disease): Dosing based on age at initial dose:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants 8 weeks to 6 months: MenACWY-CRM (Menveo): IM: 0.5 mL per dose for a total of 4 doses administered at 2, 4, 6, and 12 months of age</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 7 to 23 months (incomplete vaccination): MenACWY-CRM (Menveo): IM: 0.5 mL per dose for a total of 2 doses given at least 3 months apart; the second dose should be given at age &ge;12 months and at least 12 weeks after the first dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Persistent complement component deficiency or HIV-exposed/-infected: Dosing based on age at first dose:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants 8 weeks to 6 months: MenACWY-CRM (Menveo): IM: 0.5 mL per dose for a total of 4 doses administered at 2, 4, 6, and 12 months of age</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children 7 to 23 months:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">MenACWY-CRM (Menveo): Infants and Children 7 to 23 months: IM: 0.5 mL per dose for a total of 2 doses; the second dose should be given at age &ge;12 months and at least 12 weeks after the first dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">MenACWY-D (Menactra): Infants and Children 9 to 23 months: IM: 0.5 mL per dose for a total of 2 doses; the second dose should be given at least 3 months after the first dose. May be given as early as 8 weeks apart if needed prior to travel. <b>Note: </b>Administer before or concomitantly with DTaP and administer &ge;4 weeks after completion of all PCV doses.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Community outbreak (due to vaccine serogroup): Infants &ge;2 months to Children 23 months: Initiate or complete an age appropriate series of MenACWY-CRM (Menveo) or MenACWY-D (Menactra); see Primary immunization above for dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Travel to or residence in countries with hyperendemic or epidemic meningococcal disease: Infants 2 months to Children 23 months: Initiate or complete an age appropriate series of MenACWY-CRM (Menveo) or MenACWY-D (Menactra); see Primary immunization above for dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;2 years and Adolescents, not previously vaccinated and who have persistent complement deficiencies, functional or anatomic asplenia, or who have HIV infection: IM: 0.5 mL per dose for a total of 2 doses given 8 to12 weeks apart. If using MenACWY-D (Menactra), administer before or concomitantly with DTaP and administer &ge;4 weeks after completion of all PCV doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Other children &ge;2 years and Adolescents at increased risk not previously vaccinated and who are either: First year college students &le;21 years of age living in residential housing, traveling to or residents of areas where meningococcal disease is endemic/hyperendemic, at risk during a community outbreak, or microbiologists routinely exposed to <i>Neisseria meningitidis</i>: IM: 0.5 mL as a single dose. If using MenACWY-D (Menactra), administer &ge;4 weeks after completion of all PCV doses. College students &le;21 years should have documentation of a vaccination not more than 5 years before enrollment (preferably a dose on their 16th birthday).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Booster dose:</b> (CDC/ACIP [Cohn 2013]):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Booster vaccination for patients <b>NOT</b> at increased risk for meningococcal disease:</i> IM: 0.5 mL as a single dose. If primary vaccination was at 11 to 12 years, the booster dose should be given at age 16. If the primary vaccination was given at 13 to 15 years, the booster dose should be given at age 16 to 18. Minimum interval between MenACWY (Menveo or Menactra) doses is 8 weeks. A booster dose is not needed if the primary dose was given after the 16th birthday unless the person becomes at increased risk for meningococcal disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Booster vaccination for patients at increased risk for meningococcal disease: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If first dose received at 2 months to 6 years of age: Repeat dose 3 years after primary vaccination and every 5 years thereafter if the person remains at increased risk.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If first dose received at &ge;7 years of age: Repeat dose 5 years after primary vaccination and every 5 years thereafter if the person remains at increased risk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Primary immunization: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: Adults &le;55 years: Menactra, Menveo: IM: 0.5 mL as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CDC (ACIP) recommendations (CDC/ACIP [Cohn 2013]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Primary vaccination for persons <b>NOT</b> at increased risk for meningococcal disease: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">19 to 21 years: Not routinely recommended; may receive one 0.5 mL dose as a catch-up vaccination if no dose was received after the 16th birthday.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;22 years: Not routinely recommended; see dosing for persons at increased risk</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Primary vaccination for persons at increased risk for meningococcal disease: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adults &le;55 years not previously vaccinated and who have persistent complement deficiencies, functional or anatomic asplenia, or who have HIV infection: IM: 0.5 mL per dose for a total of two doses given 8 to 12 weeks apart. If using MenACWY-D (Menactra), administer &ge;4 weeks after completion of all PCV doses</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Other adults &le;55 years not previously vaccinated and who are either: First year college students &le;21 years of age living in residential housing, traveling to or residents of areas where meningococcal disease is endemic/hyperendemic, at risk during a community outbreak, or microbiologists routinely exposed to <i>Neisseria meningitidis</i>: IM: 0.5 mL as a single dose. If using MenACWY-D (Menactra), administer &ge;4 weeks after completion of all PCV doses. College students &le;21 years should have documentation of a vaccination not more than 5 years before enrollment (preferably a dose on their 16th birthday).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Booster dose: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Booster vaccination for persons <b>NOT</b> at increased risk for meningococcal disease:</i> Adults &le;21 years: IM: 0.5 mL as a single dose if the first dose was given prior to the 16th birthday. A booster dose is not needed if the primary dose was given after the 16th birthday unless the person becomes at increased risk for meningococcal disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Booster vaccination for persons at increased risk for meningococcal disease:</i> Adults &le;55 years: Repeat dose every 5 years if the person remains at increased risk</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192561\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, solution [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Menactra: 4 mcg each of polysaccharide antigen groups A, C, Y, and W-135 [bound to diphtheria toxoid 48 mcg] per 0.5 mL [MCV4 or MenACWY-D]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Menveo: MenA oligosaccharide 10 mcg, MenC oligosaccharide 5 mcg, MenY oligosaccharide 5 mcg, and MenW-135 oligosaccharide 5 mcg [bound to CRM<sub>197</sub> protein 32.7-64.1 mcg] per 0.5 mL (0.5 mL) [MenACWY-CRM; supplied in two vials, one containing MenA powder and one containing MenCYW-135 liquid]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192551\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25734130\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">In the U.S, the appropriate CDC-approved  Vaccine Information Statement (VIS) must be provided to the patient prior to administering each dose of this vaccine; VIS is available at <a target=\"_blank\" href=\"http://www.cdc.gov/vaccines/hcp/vis/vis-statements/mening.html&amp;token=gEYW25NhtCvZOAwXtkbVLLmS6WeorT12E9NO71eougpbAvF3HpxHX2z8Xh90fi8gFIf6lPPk0Gqgyl6RwG5R6w==&amp;TOPIC_ID=12931\" target=\"_blank\">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/mening.html</a>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060176\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IM: Administer by IM injection into midlateral aspect of the thigh in infants and small children; administer in the deltoid area to older children and adults; not for intradermal, subcutaneous, or IV administration; must administer dose within 8 hours after reconstitution. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection (ACIP [Kroger 2017]). To prevent syncope-related injuries, adolescents and adults should be vaccinated while seated or lying down (ACIP [Kroger 2017]). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192570\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Menactra: Store between 2&deg;C to 8&deg;C (35&deg;F to 46&deg;F); do not freeze. Discard product exposed to freezing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Menveo: Prior to reconstitution, store between 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Protect from light. Discard product exposed to freezing. Use immediately after reconstitution but may be stored at &le;25&deg;C (77&deg;F) for up to 8 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060175\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Provide active immunization against invasive meningococcal disease caused by <i>N. meningitidis</i> serogroups A, C, Y, and W-135 (Menactra: FDA approved 9 months to 55 years; Menveo: FDA approved in ages 2 months to 55 years).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">The Advisory Committee on Immunization Practices (ACIP) (CDC/ACIP [Cohn 2013]; CDC/ACIP [MacNeil 2014]; CDC/ACIP [MacNeil 2016]) recommends routine vaccination of:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Children and adolescents aged 11 to 18 years of age</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Persons &ge;2 months of age who are at increased risk of meningococcal disease</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Persons (in all recommended age groups) at increased risk who are part of outbreaks caused by vaccine preventable serogroups</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Those at increased risk of meningococcal disease include:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Persons &ge;2 months of age with medical conditions such as anatomic or functional asplenia (including sickle cell disease), HIV, or persistent complement component deficiencies (eg, C3, C5-C9, properdin, factor H, or factor D)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Persons &ge;2 months of age that travel to or reside in countries where meningococcal disease is hyperendemic or epidemic, especially if contact with the local population will be prolonged</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Unvaccinated or incompletely vaccinated first year college students living in residence halls</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Military recruits</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Microbiologists with occupational exposure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3343086\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">MCV (meningococcal conjugate vaccine; MCV4 is the correct abbreviation) may be confused with PCV (pneumococcal conjugate vaccine; PCV13 is the correct abbreviation)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">MCV (meningococcal conjugate vaccine; MCV4 is the correct abbreviation) may be confused with MMR (measles, mumps, and rubella virus vaccine)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Meningococcal ACWY (MenACWY) vaccine may be confused with meningococcal B (MenB) vaccine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issue:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Menactra (MCV4) should be administered by intramuscular (IM) injection only. Inadvertent subcutaneous (SubQ) administration has been reported; possibly due to confusion of this product with Menomune (MPSV4), also a meningococcal polysaccharide vaccine, which is administered by the SubQ route.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Menveo is supplied in two vials, one containing MenCYW-135 liquid and one containing MenA lyophilized powder, which must be mixed together in order to administer the recommended vaccine components. Errors have occurred when both vials have not been used or are mixed improperly, ensure proper preparation before administering.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192590\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">May vary by product and age group:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, drowsiness, excessive crying, fatigue, headache, irritability, malaise</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia, change in appetite, diarrhea, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Erythema at injection site, induration at injection site, pain at injection site, swelling at injection site, tenderness at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Acute disseminated encephalomyelitis, anaphylactoid reaction, anaphylaxis, apnea (premature infants), appendicitis, auditory impairment, Bell&rsquo;s palsy, blepharoptosis, convulsions (including tonic), Cushing&rsquo;s syndrome, dehydration, depression, equilibrium disturbance, exfoliation of skin, facial paresis, falling, febrile seizures, gastroenteritis, Guillain-Barre syndrome, hypersensitivity, hypotension, increased serum ALT, inflammation at injection site, injection site cellulitis, Kawasaki Syndrome, ostealgia, pelvic inflammatory disease, pneumonia, pruritus at injection site, seizure, simple partial seizures, staphylococcal infection, suicidal tendencies, syncope (including vasovagal), transverse myelitis, varicella, vertebral disc disease, vestibular disturbance</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192565\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Severe hypersensitivity (eg, anaphylaxis) to other meningococcal-containing vaccines or any component of the formulation including diphtheria toxoid or CRM<sub>197</sub> (a diphtheria toxin carrier protein)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192554\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Guillain-Barr&eacute; syndrome (GBS): Risk of developing GBS may be increased following vaccination in persons previously diagnosed with GBS. The risk of developing GBS was evaluated in a study of healthcare claims of persons 11 to 18 years of age (n= ~9,600,000; 15% were vaccinated with Menactra); 72 cases of GBS were confirmed and none received the vaccine within 42 days prior to symptoms; 129 reported cases of GBS could not be confirmed or excluded. Data not currently available to assess possible risk of GBS following use of Menveo. Individuals with a previous history of GBS should only receive Menactra after an assessment of risks and benefits.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Defer administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Meningococcal infections: Not to be used to treat meningococcal infections or to provide immunity against <i>N. meningitidis</i> serogroup B or diphtheria.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible; however, vaccination should not be deferred because a specific brand name is unavailable (ACIP [Kroger 2017]). Administration of Menactra (meningococcal MenACWY-D conjugate vaccine) one month after Daptacel has been shown to have reduced meningococcal antibody responses in children 4 to 6 years; these vaccines should be administered simultaneously or Menactra should be administered prior to Daptacel.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered immunocompetence: Consider deferring immunization during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]); may have a reduced response to vaccination. In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines. Inactivated vaccines should be administered &ge;2 weeks prior to planned immunosuppression when feasible; inactivated vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2017]; IDSA [Rubin 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Apnea has been reported following IM vaccine administration in premature infants; consider clinical status implications. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antipyretics: Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2017]). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Use of this vaccine for specific medical and/or other indications (eg, immunocompromising conditions, hepatic or kidney disease, diabetes) is also addressed in the ACIP Recommended Immunization Schedules (ACIP [Kim 2016]; (CDC/ACIP [Robinson 2017]). Specific recommendations for use of this vaccine in immunocompromised patients with asplenia, cancer, HIV infection, cerebrospinal fluid leaks, cochlear implants, hematopoietic stem cell transplant (prior to or after), sickle cell disease, solid organ transplant (prior to or after), or those receiving immunosuppressive therapy for chronic conditions are available from the IDSA (Rubin 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26017128\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;\">Children may have higher incidence of local adverse effects (erythema, swelling, tenderness). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299661\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192557\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12931&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Patients should receive inactivated vaccines prior to initiation of belimumab therapy whenever possible, due to the risk for an impaired response to the vaccine during belimumab therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diphtheria and Tetanus Toxoids, and Acellular Pertussis Vaccine: May diminish the therapeutic effect of Meningococcal (Groups A / C / Y and W-135) Diphtheria Conjugate Vaccine. More specifically, prior administration of the diphtheria and tetanus toxoids, and acellular pertussis vaccine may diminish antibody response to the meningococcal (groups A / C / Y / and W-135) diphtheria conjugate vaccine in some patients. Management: Administer the meningococcal (groups A / C / Y and W-135) diphtheria conjugate vaccine (Menactra brand) before or concurrently with the diphtheria and tetanus toxoids, and acellular pertussis vaccine (Daptacel brand) in children 4 to 6 years of age.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<b> Exceptions: </b>Cytarabine (Liposomal).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pneumococcal Conjugate Vaccine (13-Valent): Meningococcal (Groups A / C / Y and W-135) Diphtheria Conjugate Vaccine may diminish the therapeutic effect of Pneumococcal Conjugate Vaccine (13-Valent).  Management: It is recommended to administer PCV13 at least 4 weeks prior to the administration of MenACYW-D vaccine in persons with anatomic asplenia or functional asplenia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May diminish the therapeutic effect of Vaccines (Inactivated).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192559\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192568\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies conducted with Menactra. Limited information is available following inadvertent use of Menactra during pregnancy (Zheteyeva 2013). Patients should contact the Sanofi Pasteur Inc. vaccine registry at 1-800-822-2463 if they are pregnant or become aware they were pregnant at the time of Menactra vaccination.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Adverse events were not observed in animal reproduction studies conducted with Menveo. Limited information is available following inadvertent use of Menveo during pregnancy. Patients should contact GlaxoSmithKline at 1-877-413-4759 if they are pregnant or become aware they were pregnant at the time of Menveo vaccination.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Inactivated bacterial vaccines have not been shown to cause increased risks to the fetus (ACIP [Kroger 2017]). Pregnancy should not preclude vaccination if indicated (CDC/ACIP [Cohn 2013]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13929203\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Observe for syncope for 15 minutes following administration (ACIP [Kroger 2017]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192553\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Induces immunity against meningococcal disease via the formation of bactericidal antibodies directed toward the polysaccharide capsular components of <i>Neisseria meningitidis</i> serogroups A, C, Y and W-135.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10284076\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;margin-top:0em;display:inline\">Two meningococcal (Groups A/C/Y and W-135) diphtheria conjugate vaccines are available. Menveo uses oligosaccharides of the <i>N. meningitidis</i> serogroups linked to CRM<sub>197</sub> (a nontoxic diphtheria toxin carrier protein) and Menactra uses polysaccharides from the serogroups linked to diphtheria toxoid.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23669881\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Menactra (BB, CL, HK, IL, JP, KR, LB, MY, PH, QA, SA, SG, TH, TR);</li>\n      <li>Menacttra (AR);</li>\n      <li>Menveo (AT, BB, BE, CH, CL, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HR, HU, ID, IE, IL, KR, LB, LT, LU, LV, MT, MY, NL, NO, PH, PL, PT, QA, SA, SE, SG, SK, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Cohn AC, MacNeil JR, Clark TA, et al; Center for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2013;62(RR-2):1-28. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quadrivalent-meningococcal-conjugate-d-vaccine-pediatric-drug-information/abstract-text/23515099/pubmed\" target=\"_blank\" id=\"23515099\">23515099</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim DK, Riley LE, Harriman KH, Hunter P, Bridges CB. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(5):136-138.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quadrivalent-meningococcal-conjugate-d-vaccine-pediatric-drug-information/abstract-text/28182599/pubmed\" target=\"_blank\" id=\"28182599\">28182599</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroger AT, Duchin J, Vazquez M. General best practice guidelines for immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Available at <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf\" target=\"_blank\">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed April 4, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacNeil JR, Rubin L, McNamara L, Briere EC, et al. Use of MenACWY-CRM vaccine in children aged 2 through 23 months at increased risk for meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2013. <i>MMWR Morb Mortal Wkly Rep</i>. 2014;63(24):527-530.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quadrivalent-meningococcal-conjugate-d-vaccine-pediatric-drug-information/abstract-text/24941332 /pubmed\" target=\"_blank\" id=\"24941332 \">24941332 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacNeil JR, Rubin LG, Patton M, Ortega-Sanchez IR, Martin SW. Recommendations for use of meningococcal conjugate vaccines in HIV-infected persons - Advisory Committee on Immunization Practices, 2016. <i>MMWR Morb Mortal Wkly Rep</i>. 2016;65(43):1189-1194.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quadrivalent-meningococcal-conjugate-d-vaccine-pediatric-drug-information/abstract-text/27811836/pubmed\" target=\"_blank\" id=\"27811836\">27811836</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Menactra (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine [prescribing information]. Swiftwater, PA: Sanofi Pasteur Inc; October 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Menveo (Meningococcal [Groups A, C, Y and W-135] Oligosaccharide Diphtheria CRM197 Conjugate Vaccine) [prescribing information]. Cambridge, MA: Novartis Vaccines and Diagnostics, Onc; August 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Center for Immunization and Respiratory Diseases (NCIRD). General recommendations on immunization&mdash;recommendations of the Advisory Committee on Immunization Practices (ACIP) [published correction appears in <i>MMWR Recomm Rep</i>. 2011;60:993]. <i>MMWR Recomm Rep</i>. 2011;60(2):1-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quadrivalent-meningococcal-conjugate-d-vaccine-pediatric-drug-information/abstract-text/19837254/pubmed\" target=\"_blank\" id=\"19837254\">19837254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prymula R, Siegrist CA, Chlibek R, et al, &quot;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&quot; <i>Lancet</i>, 2009, 374(9698):1339-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quadrivalent-meningococcal-conjugate-d-vaccine-pediatric-drug-information/abstract-text/19837254/pubmed\" target=\"_blank\" id=\"19837254\">19837254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson CL, Romero JR, Kempe A, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(5):134-135.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quadrivalent-meningococcal-conjugate-d-vaccine-pediatric-drug-information/abstract-text/28182607/pubmed\" target=\"_blank\" id=\"28182607\">28182607</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quadrivalent-meningococcal-conjugate-d-vaccine-pediatric-drug-information/abstract-text/24311479/pubmed\" target=\"_blank\" id=\"24311479\">24311479</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zheteyeva Y, Moro PL, Yue X, Broder K. Safety of meningococcal polysaccharide-protein conjugate vaccine in pregnancy: a review of the Vaccine Adverse Event Reporting System. <i>Am J Obstet Gynecol</i>. 2013;208(6):478.e1-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quadrivalent-meningococcal-conjugate-d-vaccine-pediatric-drug-information/abstract-text/23453881/pubmed\" target=\"_blank\" id=\"23453881\">23453881</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12931 Version 110.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F192572\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F12592734\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1060172\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1060165\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F192561\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F192551\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F25734130\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1060176\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F192570\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1060175\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F3343086\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F192590\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F192565\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F192554\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26017128\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299661\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F192557\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F192559\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F192568\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F13929203\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F192553\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F10284076\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F23669881\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12931|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=quadrivalent-meningococcal-conjugate-d-vaccine-drug-information\" class=\"drug drug_general\">Quadrivalent meningococcal conjugate (D) vaccine: Drug information</a></li><li><a href=\"topic.htm?path=quadrivalent-meningococcal-conjugate-d-vaccine-patient-drug-information\" class=\"drug drug_patient\">Quadrivalent meningococcal conjugate (D) vaccine: Patient drug information</a></li></ul></div></div>","javascript":null}